FDA Approves LOSARTAN POTASSIUM — Lupin Pharmaceuticals, Inc.

# FDA Approves Lupin Pharmaceuticals' Generic Losartan Potassium Lupin Pharmaceuticals, Inc. received FDA approval for its generic losartan potassium oral formulation (ANDA078232), positioning the company to capture market share in the competitive antihypertensive segment as the drug's patent protections expire. The approval enables Lupin to offer a lower-cost alternative to brand-name formulations, potentially driving significant volume growth in the high-demand hypertension treatment market.